Advisor Resource Council Acquires Shares of 96,343 NeoGenomics, Inc. (NASDAQ:NEO)

Advisor Resource Council acquired a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) during the first quarter, according to its most recent filing with the SEC. The fund acquired 96,343 shares of the medical research company's stock, valued at approximately $872,000. Advisor Resource Council owned 0.07% of NeoGenomics as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the stock. Chicago Capital LLC lifted its stake in NeoGenomics by 46.6% in the 1st quarter. Chicago Capital LLC now owns 24,007 shares of the medical research company's stock worth $228,000 after purchasing an additional 7,627 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of NeoGenomics by 1,107.7% in the first quarter. GAMMA Investing LLC now owns 17,765 shares of the medical research company's stock worth $1,872,000 after purchasing an additional 16,294 shares during the period. Moody National Bank Trust Division raised its position in shares of NeoGenomics by 16.6% in the first quarter. Moody National Bank Trust Division now owns 85,347 shares of the medical research company's stock worth $810,000 after buying an additional 12,121 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of NeoGenomics by 7.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 646,111 shares of the medical research company's stock worth $10,648,000 after buying an additional 42,895 shares in the last quarter. Finally, Sovereign s Capital Management LLC bought a new stake in NeoGenomics during the fourth quarter valued at $490,000. Hedge funds and other institutional investors own 98.50% of the company's stock.

Analyst Upgrades and Downgrades

NEO has been the topic of a number of research analyst reports. Leerink Partnrs lowered NeoGenomics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Piper Sandler set a $12.00 price objective on shares of NeoGenomics and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. Leerink Partners downgraded shares of NeoGenomics from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $25.00 to $9.00 in a research note on Wednesday, April 30th. The Goldman Sachs Group cut their price target on shares of NeoGenomics from $15.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Finally, Morgan Stanley decreased their price target on shares of NeoGenomics from $17.00 to $10.00 and set an "equal weight" rating on the stock in a report on Thursday, May 1st. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $13.83.

Insider Activity at NeoGenomics

In other news, CEO Anthony P. Zook bought 18,900 shares of the company's stock in a transaction dated Tuesday, May 6th. The stock was bought at an average cost of $7.88 per share, for a total transaction of $148,932.00. Following the completion of the acquisition, the chief executive officer now owns 18,900 shares in the company, valued at approximately $148,932. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Jeffrey Scott Sherman purchased 20,000 shares of NeoGenomics stock in a transaction that occurred on Friday, May 2nd. The shares were acquired at an average price of $7.51 per share, for a total transaction of $150,200.00. Following the acquisition, the chief financial officer now owns 158,494 shares in the company, valued at $1,190,289.94. This trade represents a 14.44% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 70,600 shares of company stock worth $550,438 in the last ninety days. 2.40% of the stock is owned by company insiders.

NeoGenomics Trading Down 0.7%

Shares of NEO traded down $0.05 during mid-day trading on Wednesday, reaching $7.18. The company's stock had a trading volume of 1,253,152 shares, compared to its average volume of 1,269,133. NeoGenomics, Inc. has a 52 week low of $6.08 and a 52 week high of $19.12. The stock has a market cap of $924.07 million, a PE ratio of -11.77 and a beta of 1.65. The company's fifty day moving average price is $7.91 and its two-hundred day moving average price is $11.24. The company has a current ratio of 2.05, a quick ratio of 1.95 and a debt-to-equity ratio of 0.38.

NeoGenomics (NASDAQ:NEO - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.06). NeoGenomics had a negative return on equity of 2.21% and a negative net margin of 11.54%. The business had revenue of $168.04 million during the quarter, compared to the consensus estimate of $171.38 million. During the same period in the prior year, the firm earned ($0.02) earnings per share. The business's revenue for the quarter was up 7.6% on a year-over-year basis. On average, analysts predict that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.